Compare PFX & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | LITS |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 62.9M |
| IPO Year | N/A | N/A |
| Metric | PFX | LITS |
|---|---|---|
| Price | $44.33 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 466.7K |
| Earning Date | 12-12-2025 | 11-17-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | ★ $25,262,322.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.09 | ★ N/A |
| Revenue Growth | ★ 13.89 | N/A |
| 52 Week Low | $41.00 | $1.46 |
| 52 Week High | $57.40 | $9.00 |
| Indicator | PFX | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | N/A |
| Support Level | $41.50 | N/A |
| Resistance Level | $42.00 | N/A |
| Average True Range (ATR) | 0.60 | 0.00 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 100.00 | 0.00 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.